Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00279253
Other study ID # OPHT-141003
Secondary ID
Status Completed
Phase Phase 4
First received January 18, 2006
Last updated January 18, 2006
Start date March 2004
Est. completion date January 2005

Study information

Verified date January 2006
Source Medical University of Vienna
Contact n/a
Is FDA regulated No
Health authority Austria: Bundesministerium für Gesundheit und Frauen
Study type Interventional

Clinical Trial Summary

Background Clonidine, a derivate of Imidazol, is an antihypertensive drug. It acts by stimulating adrenergic receptors on nerves in the brain and Imidazol-receptors. As a result, clonidine slows the heart rate and reduces blood pressure. Clonidine was approved by the FDA in 1974 and is registered in Austria with the brand name “Catapresan”.

Alpha2 adrenergic agonists are nowadays used topically as eye drops in glaucoma treatment. In addition to their known effect of lowering intraocular pressure, alpha2 adrenoceptor agonists are neuroprotective. Brimonidine, which is the most commonly used topical alpha-2 agonist, is currently on the market for treatment of glaucoma and is effective in reducing intraocular pressure. It has, however, been shown that brimonidine is a very potent vasoconstrictor in the ciliary body thus reducing aqueous humor production. Little is, however, known about potential vasoconstrictor effects of brimonidine in the posterior pole of the eye. This is of clinical importance, because optic nerve head ischemia appears to contribute to glaucoma pathophysiology. Direct investigation of the ocular hemodynamic effects of brimonidine is, however, difficult, because lowering intraocular pressure with brimonidine may confound the results due to the concomitant change in ocular perfusion pressure.

The aim of the present study is to assess the effect of intravenous clonidine as model drug of alpha agonists on ocular blood flow and IOP in healthy humans.

Study objectives:

To investigate effects of clonidine on ocular blood flow and intraocular pressure.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date January 2005
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 19 Years to 35 Years
Eligibility Inclusion Criteria:

Men aged between 19 and 35 years, nonsmokers

Body mass index between 15th and 85th percentile

Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant

Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant

Normal ophthalmic findings, ametropy < 3 Dpt.

Exclusion Criteria:

Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study

Treatment in the previous 3 weeks with any drug

Symptoms of a clinically relevant illness in the 3 weeks before the first study day

History of hypersensitivity to the trial drug or to drugs with a similar chemical structure

History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with, distribution, metabolism or excretion of study drugs

Blood donation during the previous 3 weeks

History or family history of epilepsy

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
clonidine (drug) intravenously


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Vienna

Outcome

Type Measure Description Time frame Safety issue
Primary ocular blood flow
See also
  Status Clinical Trial Phase
Completed NCT04508270 - Significance of Early Mobilization After VATS-L
Completed NCT05604339 - Study of Recovery and Blood Rheology Changes in Ultra-endurance Runners (ERUPTION-3)
Completed NCT03705936 - Metaplasticity in Human Pharyngeal Motor Cortex N/A
Completed NCT03807258 - Functional Implication of Corpus Callosum in Voluntary Strength in COPD Patients N/A
Active, not recruiting NCT02839070 - Influence of Sleep Regularity on Circadian Rhythms, Learning, Performance, and Mood N/A
Completed NCT02850367 - Effect of NO Precursors on Physiological Responses to Exercise N/A
Completed NCT02778659 - Hypnotic Intake and Motor and Cognitive Performances at High Altitude N/A
Completed NCT02408003 - Changes in Cardiac Deformation Following Physiologic Alterations and Inotropic Support. N/A
Recruiting NCT02940184 - GLP-1 Signaling in Truncally Vagotomized Subjects N/A
Completed NCT03368703 - Physiopathology of Lower Cortical Activation in COPD Patients: Contribution of Cortical Neuromodulation N/A
Completed NCT03424551 - Vibration Induced Reflex Responses and Estimation of TVR N/A
Recruiting NCT02672722 - Assessment of the Changes in Cortical and Medullary Renal Blood Flow During Exercise in Healthy Subjects Using Contrast Enhanced Ultrasound Phase 1/Phase 2
Recruiting NCT01685307 - Impact of Cooking Process on Meat Protein Digestion and Metabolism N/A
Completed NCT01154582 - Nutritional Quality of Egg Proteins and Effect on Satiety N/A
Completed NCT05362383 - Use of TENS for the Recovery of Oral Function After Orthognathic Surgery N/A
Recruiting NCT05168501 - Assessing Variability of the Ventilatory Response to Duffin's Rebreathing Procedure N/A
Completed NCT03751410 - Chronic Ibrutinib Therapy Effect on Left Atrial Function
Completed NCT01079624 - GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose Phase 1
Recruiting NCT04391465 - Assessment of the Relationship Between Cerebral Blood Flow and Heart Rate N/A
Completed NCT03916770 - The Effect of Whole Body Vibration (WBV) on Spasticity in Poststroke Hemiplegia N/A